目的 探討強(qiáng)骨膠囊聯(lián)合依托考昔片治療膝骨性關(guān)節(jié)炎的臨床療效。方法 選取2021年3月—2022年12月安陽市人民醫(yī)院收治的88例膝骨性關(guān)節(jié)炎患者作為研究對象,根據(jù)隨機(jī)數(shù)字表法將所有患者分為對照組和治療組,每組各44例。對照組口服依托考昔片,1片/次,1次/d。治療組在對照組基礎(chǔ)上口服強(qiáng)骨膠囊,1粒/次,3次/d。兩組患者連續(xù)治療1個月。觀察兩組的臨床療效,比較兩組患者膝關(guān)節(jié)活動度、主觀疼痛程度、病情程度和關(guān)節(jié)液炎性因子水平。結(jié)果 治療后,治療組的總有效率為95.45%,高于對照組的總有效率79.55%,組間比較差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組的屈曲角度、過伸角度明顯高于治療前(P<0.05);治療后,治療組的屈曲角度、過伸角度明顯高于對照組(P<0.05)。治療后,兩組的視覺模擬評分法(VAS)、骨性關(guān)節(jié)炎評估量表(WOMAC)評分均明顯低于治療前(P<0.05),且治療組VAS、WOMAC評分均明顯低于對照組(P<0.05)。治療后,兩組關(guān)節(jié)液中基質(zhì)金屬蛋白酶-13(MMP-13)、金屬蛋白酶組織抑制因子-1(TIMP-1)、腫瘤壞死因子-α(TNF-α)水平均顯著低于治療前(P<0.05),且治療組的關(guān)節(jié)液中MMP-13、TIMP-1、TNF-α水平明顯低于對照組(P<0.05)。結(jié)論 強(qiáng)骨膠囊聯(lián)合依托考昔片治療膝骨性關(guān)節(jié)炎療效確切,能提高膝關(guān)節(jié)活動度,減輕疼痛和病情,降低炎癥損傷,且安全性良好。

Objective To investigate the clinical effect of Qianggu Capsules combined with Etocoxi Tablets in treatment of knee osteoarthritis.Methods Patients(88 cases) with knee osteoarthritis in the People's Hospital of Anyang City from March 2021 to December 2022 were divided into control and treatment groups according to the random number table method, and each group had 44cases. Patients in the control group were po administered with Etocoxi Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Qianggu Capsules on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the knee joint range of motion, subjective pain level, severity of illness, and levels of inflammatory factors in joint fluid in two groups were compared.Results After treatment, the total effective rate of the treatment group was 95.45%, which was higher than that of the control group(79.55%), and the difference between groups was statistically significant(P<0.05). After treatment, the flexion angle and hyperextension angle of two groups were significantly higher than before treatment(P<0.05). After treatment, the flexion angle and hyperextension angle in the treatment group were significantly higher than those in the control group(P<0.05). After treatment, the VAS scores and WOMAC scores of two groups were significantly lower than before treatment(P<0.05), and the VAS scores and WOMAC scores of the treatment group were significantly lower than those of the control group(P<0.05). After treatment, the levels of MMP-13, TIMP-1, and TNF-α in joint fluid of two groups were significantly lower than before treatment(P<0.05), and the levels of MMP-13, TIMP-1, and TNF-α in joint fluid of two groups were significantly lower than those of control group(P<0.05).Conclusion Qianggu Capsules combined with Etocoxi Tablets has definite efficacy in treatment of knee osteoarthritis, which can reduce pain and disease, improve knee motion,reduce inflammation and injury, and has good safety.

R977

河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題(20-21ZY2024)